Skip to content

Portable Detection, Assessment, and Control of Trace Aluminum Ions in Parenteral Nutrition Formulations for Preterm Infants

Portable Detection, Assessment, and Control of Trace Aluminum Ions in Parenteral

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07646925
Acronym
PN-Al POCT
Enrollment
250
Registered
2026-06-15
Start date
2026-07-01
Completion date
2027-12-31
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trace Aluminum Ions in Parenteral Nutrition

Brief summary

The research team will develop a series of multivalent nanozyme materials (MOF@Arg@His) to construct a sensing platform with dual-mode colorimetric and fluorescent responses, thereby markedly improving the sensitivity and selectivity for aluminum ion detection. By incorporating machine-learning algorithms, a signal-correction model will be established to enable highly accurate quantification of aluminum ions in complex matrices. Based on a clinical observational cohort, samples of PN raw materials, compounded admixtures, and infant biospecimens will be collected to systematically quantify aluminum exposure levels in preterm infants and to assess the associated risks of relevant complications. Integrating cutting-edge technological innovation with strong clinical applicability, this project aims to build a full-chain "formulation-exposure-outcome" evaluation framework, providing an intelligent detection tool and risk early-warning evidence base to enhance medication safety in neonates.

Interventions

None listed

Sponsors

Han Tongyan
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Days to 1 Days
Healthy volunteers
Yes

Inclusion criteria

* Preterm infants receiving parenteral nutrition (PN) in the Neonatal Intensive Care Unit (NICU) of Peking University Third Hospital, with gestational age \<37 weeks, PN administered for ≥5 days, complete clinical records, and written informed consent from parents/legal guardians.

Exclusion criteria

* Infants with severe inborn errors of metabolism, major congenital malformations, early death, or incomplete data will be excluded.

Design outcomes

Primary

MeasureTime frameDescription
Aluminum exposure levelFrom birth to 4 weeks postnatal age.Cumulative aluminum exposure from parenteral nutrition will be calculated for each infant based on the measured aluminum concentration in each PN component and the daily administered volume or dose. Exposure will be expressed as μg/kg/day and cumulative μg/kg over the first 4 weeks of postnatal life. Aluminum concentrations will be measured using inductively coupled plasma mass spectrometry, or the actual validated assay used in the study.

Secondary

MeasureTime frameDescription
Complications in preterm infantsFrom birth to 4 weeks postnatal ageIncidences of prematurity-related complications such as feeding intolerance, necrotizing enterocolitis, bronchopulmonary dysplasia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 16, 2026